XRCC1 genetic polymorphisms and bladder cancer susceptibility:: A meta-analysis
XRCC1 genetic polymorphisms and bladder cancer susceptibility:: A meta-analysis
复制标题
DOI：
10.1016/j.urology.2007.12.059
复制
发表时间：
2008-10-01
期刊：
影响因子：
2.1
通讯作者：
Han, Ruifa
中科院分区：
文献类型：
--
作者：
Wang, Chunyang;Sun, Yan;Han, Ruifa
目的探讨X射线修复交叉互补组1（XRCC 1）基因Arg（194）Trp、Arg（280）His和Arg（399）Gln多态性与膀胱癌易感性的关系。结果共检索到10份合格报告，其中病例组3749份，对照组3947份。对于Arg（194）Trp（6项研究，3091例病例，3219例对照），没有证据表明携带变异基因型（Trp/Trp + Arg/Trp）的个体相对于携带野生纯合子Arg/Arg基因型的个体，膀胱癌的风险降低（比值比[OR] 0.90，95%置信区间[CI] 0.77至1.05; P = 0.17）。对于Arg（280）His（3项研究，2547例病例，1784例对照），与Arg/Arg基因型相比，His/His+Arg/His基因型个体患膀胱癌的风险无显著性差异（OR 0.99，95%CI 0.55 ~ 1.77; P = 0.97）。对于Arg（399）Gln（10项研究，3729例病例，3927例对照），Gln/Gln基因型携带者与Arg/Arg基因型个体相比，癌症风险并没有降低（OR 0.95，95%CI 0.82 - 1.10; P = 0.48）。同样，在隐性和显性建模中也没有发现任何关联（Gln/Gln对Arg/Gln+Arg/Arg：OR 0.92，95% CI 0.80 - 1.05; P = 0.23; Arg/Gln+Gln/Gln对Arg/Arg：OR 1.04，95% CI 0.95 - 1.14;结论XRCC 1基因Arg（194）Trp、Arg（280）His、Arg（399）Gln多态性与膀胱癌易感性无关。
OBJECTIVES To examine the association between three x-ray repair cross-complementing group 1 (XRCC1) genetic polymorphisms (Arg(194)Trp, Arg(280)His, and Arg(399)Gln) and bladder cancer susceptibility.METHODS A comprehensive search was conducted to identify all case-control studies of XRCC1 polymorphisms and bladder cancer risk. Statistical analysis was performed with the software program Review Manage, version 4.2.RESULTS A total of 10 eligible reports, including 3749 cases and 3947 controls, were identified. For Arg(194)Trp (six studies, 3091 cases, 3219 controls), no evidence indicated that individuals carrying the variant genotypes (Trp/Trp + Arg/Trp), relative to those carrying the wild homozygote Arg/Arg genotype, had a decreased risk of bladder cancer (odds ratio [OR] 0.90, 95% confidence interval [CI] 0.77 to 1.05; P = 0.17). For Arg(280)His (three studies, 2547 cases, 1784 controls), individuals with His/His+Arg/His genotypes had no significant risk of bladder cancer, compared with those with the Arg/Arg genotype (OR 0.99, 95% CI 0.55 to 1.77; P = 0.97). For Arg(399)Gln (10 studies, 3729 cases, 3927 controls), the Gln/Gln genotype carriers did not have a decreased cancer risk compared with those individuals with the Arg/Arg genotype (OR 0.95, 95% CI 0.82 to 1.10; P = 0.48). Similarly, no associations were found in the recessive and dominant modeling (Gln/Gln versus Arg/Gln+Arg/Arg: OR 0.92, 95% CI 0.80 to 1.05; P = 0.23; Arg/Gln+Gln/Gln versus Arg/Arg: OR 1.04, 95% Cl 0.95 to 1.14; P = 0.36).CONCLUSIONS No association was found between the polymorphisms in XRCC1 (Arg(194)Trp, Arg(280)His, Arg(399)Gln) and bladder cancer susceptibility.